Amyris and ImmunityBio JV for next gen Covid-19 RNA vaccine
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
A toll-free helpline to be set up to help doctors and patients
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Subscribe To Our Newsletter & Stay Updated